Details of the Drug Combinations

General Information of This Drug (ID: DMZXF05)

• Drug Name: GTx-024 (DMZXF05)
• Synonyms: (R)-Ostarine; 1132656-73-5; (2R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide; C19H14F3N3O3; 841205-47-8 pound not1202044-20-9; SCHEMBL2197534; CHEBI:94527; DTXSID70649384; BCPP000135; AOB87717; ZINC35793633; BCP9001038; NCGC00408913-01; AS-17044; FT-0673314; Y0247; 370C134; I06-2154; BRD-K16621777-001-01-9; (R)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide

Indication

Muscle atrophy; ICD 11: FB32.Y; Status: Phase 3 [1]; Breast cancer; ICD 11: 2C60-2C65; Status: Phase 2 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GTx-024 + Idarubicin	DCAS6BE	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Semaglutide + GTx-024	DCYV615	Semaglutide	Muscle Loss	[4]

References

• [1] ClinicalTrials.gov (NCT01355497) Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT06282458) Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt